Skip to main content

Multiple Myeloma

Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study
Abstract #CT04
Read More
Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Patients with Multiple Myeloma Receiving Lenalidomide, Bortezomib, and Dexamethasone
Abstract #CT02
Read More
Optimizing Daratumumab Infusion: Assessing the Safety and Feasibility of Omitting Preinfusion Medications and Decreasing Infusion Time
Justine Preedit, PharmD; Anya Yudchyts, PharmD, BCOP
Read More
Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma
Read More
Olanzapine versus Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Patients Receiving Single-Day High-Dose Melphalan
Ekim Ekinci, PharmD, MS, BCOP; James E. Cox, PharmD, BCOP; Joe E. Ensor, PhD; Edward T. McLean, PharmD, BCOP; Carlos A. Ramos, MD; Premal D. Lulla, MD; Rammurti T. Kamble, MD; George Carrum, MD
Read More
IKEMA Study: Isatuximab plus Carfilzomib and Dexamethasone in Patients with RRMM
Read More
In Patients with RRMM, Idecabtagene Vicleucel, a BCMA-Directed CAR T-Cell Therapy: CRB-401 Study Updates
Read More
CARTITUDE-1: In Patients with RRMM, Ciltacabtagene Autoleucel, a BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy
Read More
In Patients with RRMM Teclistamab, a BCMA × CD3 Bispecific Antibody: Phase 1 Study Updates
Read More
In Patients with RRMM, REGN5458, a BCMA × CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses
Read More
Page 7 of 11
Results 61 - 70 of 106